Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.925
-0.005 (-0.53%)
At close: Apr 28, 2026, 4:00 PM EDT
0.920
-0.005 (-0.54%)
After-hours: Apr 28, 2026, 7:57 PM EDT
Genprex Employees
Genprex had 13 employees as of December 31, 2025. The number of employees decreased by 3 or -18.75% compared to the previous year.
Employees
13
Change (1Y)
-3
Growth (1Y)
-18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,248,381
Market Cap
8.52M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| BioAtla | 41 |
| Bolt Biotherapeutics | 23 |
| CalciMedica | 16 |
| NuCana | 12 |
| Aprea Therapeutics | 8 |
| Quoin Pharmaceuticals | 5 |
| Creative Medical Technology Holdings | 4 |
GNPX News
- 13 hours ago - Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting - PRNewsWire
- 6 days ago - Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting - PRNewsWire
- 7 days ago - Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy - PRNewsWire
- 8 days ago - Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - PRNewsWire
- 5 weeks ago - Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting - PRNewsWire
- 7 weeks ago - Genprex to Participate at BIO Europe Spring 2026 - PRNewsWire
- 2 months ago - Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - PRNewsWire
- 2 months ago - Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - PRNewsWire